Context Therapeutics Inc. (CNTX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$0.3457−$0.0254 (−6.84%) on the dayAs of the close; data may be delayed.
CNTX price, last 12 months
Key stats
- Previous close
- $0.3711
- Open
- $0.3712
- Day range
- $0.3445 – $0.3802
- 52-week range
- $0.3434 – $3.62
- Volume
- 1.3M
- Avg volume (20 days)
- 1.3M
- Market cap
- $31.8M
Performance
1W−6.1%
1M−18.4%
3M−40.4%
6M−86.4%
YTD−76.5%
1Y−63.8%
vs S&P 500, 1Y−80.5 pts
Technicals and fundamentals
About Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $31.8M